L'intérêt à découvert pour Jazz Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Jazz Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Rapport sur les intérêts à découvert

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

JAZZ PHARMACEUTICALS ORD

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the &quot;Value&quot; category. When paired with a high Zacks Rank, &quot;A&quot; grades in the Value category are among the strongest value stocks on the market today.
One company to watch right now is Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>). JAZZ is currently sporting a Zacks Rank of #2 (Buy) and an A for Value.
Investors should also note that JAZZ holds a PEG ratio of 1.05. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock&#39;s expected earnings growth rate. JAZZ&#39;s PEG compares to its industry&#39;s average PEG of 2.21. JAZZ&#39;s PEG has been as high as 1.44 and as low as 0.64, with a median of 1.05, all within the past year.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock&#39;s price with the company&#39;s sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. JAZZ has a P/S ratio of 1.76. This compares to its industry&#39;s average P/S of 3.11.
Finally, investors will want to recognize that JAZZ has a P/CF ratio of 5.74. This metric focuses on a firm&#39;s operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. JAZZ&#39;s P/CF compares to its industry&#39;s average P/CF of 11.35. Over the past year, JAZZ&#39;s P/CF has been as high as 43.45 and as low as 5.21, with a median of 7.66.
These are just a handful of the figures considered in Jazz Pharmaceuticals&#39;s great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that JAZZ is an impressive value stock right now.
<a href="https://www.zacks.com/stock/news/2344006/is-jazz-pharmaceuticals-jazz-stock-undervalued-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_2-2344006">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Mid Cap

News

Markets

Analyst Ratings

Trading Ideas

General

JAZZ

Is Jazz Pharmaceuticals Stock Undervalued Right Now?

The well-known cannabis-based pharmaceutical drug Epidiolex, primarily used to treat childhood epilepsy, may offer relief to veterans suffering from Gulf War Illness (GWI), according to new research.
A new study on rats shows the potential of <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a>, the FDA-approved cannabidiol (CBD) drug produced by Jazz Pharmaceuticals PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>)&#8217;s GW Pharmaceuticals, in addressing cognitive, mood and pain-related symptoms of GWI, a condition linked to chemical exposures during the 1990-1991 Gulf War.
The research, conducted by Chinese scientists, was first <a href="https://hemptoday.net/early-study-shows-epidiolex-may-have-potential-as-treatment-for-illness-in-veterans/">reported</a> by&nbsp;Hemp Today.
<h3 class="wp-block-heading">Cognitive And Pain Improvements Observed</h3>
The research, <a href="https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-024-00563-2#Sec23">published</a> in Military Medical Research, reveals that long-term oral administration of CBD could alleviate cognitive impairments, mood disorders and chronic pain.
Rats treated with Epidiolex showed significant improvements in object recognition and memory retention, which are common areas of dysfunction in veterans with GWI. Additionally, CBD treatment helped ease anhedonia— the inability to experience pleasure— and reduced pain sensitivity.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
GWI, which affects 25% to 32% of the 700,000 veterans who served in Operation Desert Storm, stems from exposure to environmental hazards like pesticides, burning oil wells and chemical agents.
Veterans experience chronic fatigue, muscle and joint pain, gastrointestinal issues, respiratory problems, cognitive dysfunction and headaches. The study highlights CBD's ability to target brain pathways linked to neuroinflammation and oxidative stress, both of which worsen GWI symptoms. In this manner, these findings add to the general notion of cannabis helping Veterans to overcome the consequences of war-related activity.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28637449/thc-is-beneficial-for-ptsd-treatment-new-study-reveals">THC Is Beneficial For PTSD Treatment, New Study Reveals</a>
<h3 class="wp-block-heading">Veterans, Cannabis And War-Related Ailments</h3>
Unlike previous treatments such as curcumin or melatonin, Epidiolex proved effective at lower doses, reducing the risk of side effects. The 20 mg/kg dose used in rats equates to about 3.2 mg/kg for humans, offering a more efficient solution compared to other treatments. 
The research also notes that Epidiolex didn't impact motor function, confirming &#8220;an excellent safety profile even when taken long-term in low doses, with no observed harmful effects.&#8221;
Despite these promising results, the study emphasizes the need for further research, especially regarding potential drug interactions. 
While CBD offers hope for veterans with GWI, comprehensive clinical studies are essential before it can become a widespread treatment. 
This study, adds to the growing body of research on CBD showing medical uses for cannabis and war-related illnesses, such as <a href="https://www.benzinga.com/markets/cannabis/24/06/39381895/17-us-veterans-take-their-own-lives-everyday-heres-how-one-cannabis-company-is-trying-to-help">PTSD</a> and <a href="https://www.benzinga.com/24/07/39774432/new-study-shows-high-use-of-medical-cannabis-for-chronic-pain-and-arthritis-in-older-patients">chronic pain</a>.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39381895/17-us-veterans-take-their-own-lives-everyday-heres-how-one-cannabis-company-is-trying-to-help">17 US Veterans Take Their Own Lives Everyday, Here&#8217;s How One Cannabis Company Is Trying To Help</a></li>
</ul>
Cover: AI generated image

Cannabis

Economics

Media

FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms

Health Care

Jazz Pharmaceuticals Announced Updated Data, Including Median Progression-free Survival And Overall Survival Findings, From The Phase 2 Trial Of Zanidatamab, In Combination With Chemotherapy As First-line Treatment For HER2-expressing Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $205 price target.

Price Target

Reiteration

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $205 Price Target

Analysts' ratings for Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $164.5, accompanied by a high estimate of $210.00 and a low estimate of $113.00. This current average has decreased by 3.24% from the previous average price target of $170.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1725904914_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$222.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Jazz Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Understanding the Numbers: Jazz Pharmaceuticals's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 6.95% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 16.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 4.52%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 1.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals

Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $140 price target.

Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. Presentations include data from trials of zanidatamab and Zepzelca&#xAE; (lurbinectedin).
New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). Additional data from a Phase 2 study evaluating zanidatamab in combination with chemotherapy and bevacizumab as first-line treatment in HER2-positive metastatic colorectal cancer demonstrating encouraging antitumor activity will be presented as a mini-oral presentation at the congress.

Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress

Axsome Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.
A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.
Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.
Year to date, shares of Axsome have rallied 20.1% against the industry&#39;s decrease of 0.9%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/61/76711.jpg?v=1627352938" />
Image Source: Zacks Investment Research
The FDA issued a complete response letter to the first NDA for AXS-07 in April 2022 as it identified issues related to the chemistry, manufacturing and controls.
The NDA re-submission for AXS-07 for the acute treatment of migraine was completed during the second quarter of 2024. The FDA has not requested any additional safety or efficacy data for the NDA resubmission.
The NDA re-submission was earlier expected to be filed during the second half of 2023.
<h2>FDA Nod for AXS-07 to Diversify AXSM&#39;s Product Portfolio</h2>
Axsome currently has two marketed products in its commercial portfolio &ndash; Auvelity (AXS-05) for major depressive disorder and Sunosi (solriamfetol) for narcolepsy. A potential FDA nod for AXS-07 will diversify Axsome&#39;s commercial portfolio
Auvelity was launched in the United States in 2022 for the treatment of MDD, making it the first approved drug in the company&#39;s portfolio. The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand.
Axsome&#39;s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Axsome currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 50.6%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 49.9%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 22.2%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2332290/fda-accepts-axsm-s-nda-resubmission-for-migraine-drug-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2332290">To read this article on Zacks.com click here.</a>

Earnings Beats

Small Cap

AXSM

FULC

KRYS

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

The notes will be general unsecured obligations of the Issuer and will accrue interest payable semiannually in arrears on&nbsp;March 15&nbsp;and&nbsp;September 15&nbsp;of each year, beginning on&nbsp;March 15, 2025, at a rate of&nbsp;3.125%&nbsp;per year. The notes will mature on&nbsp;September 15, 2030, unless earlier exchanged, redeemed or repurchased. Prior to&nbsp;June 15, 2030, the notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.&nbsp;

Jazz Pharmaceuticals Launches $850M Senior Notes Offering And Kicks Off Share Buyback Strategy

Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to approximately&nbsp;$350 million&nbsp;of the term loans outstanding under the credit agreement and the remainder for general corporate purposes.&nbsp;

Buybacks

Jazz Intends To Offer $850M Of Exchangeable Senior Notes Due 2030 In Private Offering; Plans Concurrent Ordinary Share Repurchases Up To $150M Of Its Ordinary Shares

Jazz Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) and Hikma Pharmaceuticals Plc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HKMPF#OTC">HKMPF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HKMPY#OTC">HKMPY</a>) are set to face allegations that they conspired to delay the release of a generic version of Jazz&#8217;s blockbuster narcolepsy drug, Xyrem, resulting in higher <a target="_blank" href="https://www.benzinga.com/quote/jazz" rel="noreferrer noopener">prices for health plans</a>.
Narcolepsy is&nbsp;a rare, chronic neurological disorder that affects the brain&#8217;s ability to control sleep-wake cycles.
The ruling, issued by U.S. District Judge Richard Seeborg in California, allows the case to proceed to trial, though some claims have been dismissed.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39417291/why-is-jazz-pharmaceuticals-stock-trading-lower-on-thursday" rel="noreferrer noopener">Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?</a>
The plaintiffs, including Blue Cross Blue Shield Association, the city of Providence, Rhode Island, and the New York State Teamsters Council Health and Hospital Fund, argue that Jazz violated U.S. antitrust laws.
They allege that the company made monetary payments to delay the entry of a rival generic and monopolized distribution using a single specialty pharmacy.
Reuters report notes that the plaintiffs also claim that Jazz significantly increased the price of Xyrem by more than 800% between 2007 and 2014. In 2021, Xyrem generated over $1.8 billion in revenue for Jazz.
Jazz has denied the allegations, stating that the judge&#8217;s order significantly reduced the plaintiffs&#8217; claims and expressed confidence in its legal defenses.
The company also argued that its distribution strategy was approved by a U.S. regulatory agency and emphasized that other narcolepsy treatments are available.
Hikma&#8217;s generic version of Xyrem only reached the market last year, following a 2017 settlement that the plaintiffs allege was an unlawful &#8220;reverse payment agreement&#8221; designed to delay competition.
A status hearing for the case is scheduled for October.
Price Action: JAZZ stock is up 0.49% at $115.38&nbsp;at last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40607891/chewys-active-customers-growth-first-time-since-q1-fy23-is-encouraging-jp-morgan-an" target="_blank" rel="noreferrer noopener">Chewy&#8217;s Active Customers Growth First Time Since Q1 FY23 Is Encouraging: JP Morgan Analyst</a>.</li>
</ul>

Large Cap

Legal

HKMPF

HKMPY

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

In 2023, São Paulo enacted a law enabling the dispensing of cannabidiol (CBD)-based medicines across public and private health facilities associated with the Brazilian Unified Health System in Brazil&#8217;s most populous state with more than 44 million people. The law made CBD-based medicine accessible and free.
The reform happened thanks to Brazilian mothers who fought for a decade for their children&#8217;s life-saving medicine. They used every means they could think of – civil disobedience, court petitions, marches and politics, <a href="https://apnews.com/article/brazil-sao-paulo-medical-marijuana-epilepsy-d50fb583aa401bbed2af4aef5ec851b9" target="_blank" rel="noreferrer noopener">writes</a> Gabriela Sá Pessoa for the Associated Press.
Janaína Silva is a mother of a four-year-old boy, Murillo, who has Lennox-Gastaut syndrome, a rare, complex and severe type of epilepsy that is usually diagnosed before the age of four. She shared the story of how CBD has helped reduce his seizures.
"From five minutes of agony, it's now just seconds," Silva said. Only a few months ago, Murillo's seizures would have lasted much longer and would have been more intense. Now, thanks to a regular dose of liquid CBD acquired for free through the state public health system, his seizures are significantly reduced.
In a drugstore, a 30-milliliter bottle of CBD that Murillo uses costs around 800 reais ($180), which is more than half of his mother's monthly wage as an office assistant. The federal government has not made CBD-based medical products accessible for free at the national level. More moms are pushing hard to change this.
Maria Aparecida Carvalho, 56, a former bank employee is one of those moms leading the fight. Her daughter, Clárian, was diagnosed with another rare type of epilepsy called Dravet Syndrome, wrote Sá Pessoa. This type of epilepsy is so severe that it can cause sudden death. When all other medications failed, she decided to try the alternative – CBD. With the help of a lawyer, Carvalho was granted special court permission to start growing marijuana at home and has been producing the extract for her daughter and 200 other patients.
Carvalho was inspired by the story of Charlotte Figi.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h2 class="wp-block-heading">Charlotte Figi – Entire Movement</h2>
Charlotte, born with Dravet Syndrome, became famous worldwide after appearing in the <a href="https://www.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/index.html" target="_blank" rel="noreferrer noopener">2013 CNN documentary</a> hosted by Dr. Sanjay Gupta called &#8220;Weed.&#8221; She &#8220;was seizing 50 times a day, on life support, her prognosis looking worse by the day,&#8221; Charoltte's mother Paige Figi<a href="https://www.benzinga.com/markets/cannabis/24/03/37629667/time-is-still-the-enemy-says-mom-who-moved-mountains-for-her-epileptic-daughter-still-advocates-" target="_blank" rel="noreferrer noopener"> previously told Benzinga</a>. &#8220;I turned to scientists studying Cannabidiol as a potential therapy for epilepsy. I searched for experts in Colorado to help create an extract under strict breeding, farming, extracting, and testing criteria…what we now call CBD.&#8221;
It turned out that this non-intoxicating hemp extract, high in CBD and low in THC was extremely effective in treating Charlotte&#8217;s epilepsy, allowing her to live a non-medical, pharmaceutical-free life.
Charlotte inspired the creation of <a href="https://www.benzinga.com/topic/epidiolex" target="_blank" rel="noreferrer noopener">Epidiolex</a>, the groundbreaking FDA-approved cannabinoid seizure medication. The first <a href="https://www.benzinga.com/markets/cryptocurrency/18/06/11929452/gw-pharmas-epidiolex-becomes-first-cannabis-based-fda-approved" target="_blank" rel="noreferrer noopener">FDA-authorized CBD medicine</a> Jazz Pharmaceuticals&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" target="_blank" rel="noreferrer noopener">for treating seizures related to tuberous sclerosis complex</a>.
Charlotte Figi was the catalyst, or as Gupta said she was &#8220;more than an individual, she was an entire movement.&#8221; Indeed, the movement impacted the entire planet.
Read Also: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/23/03/31382701/exclusive-cannabis-saved-my-kid-psychedelics-saved-me-heather-jackson-talks-about-taboo-plant-me" rel="noreferrer noopener">EXCLUSIVE: &#8216;Cannabis Saved My Kid, Psychedelics Saved Me,&#8217; Heather Jackson Talks About Taboo Plant Medicine</a>
<h2 class="wp-block-heading">Cannabis In Brazil</h2>
Medical marijuana use in Brazil is growing. According to data from a business intelligence company, Kaya Mind, the number of medical marijuana users grew 130% from 2022 to 2023, with more than 430,000 Brazilians receiving treatment last year.
In June, Brazil's Supreme Court <a href="https://www.benzinga.com/markets/cannabis/24/06/39493683/brazils-supreme-court-decriminalizes-cannabis-possession-for-personal-use" target="_blank" rel="noreferrer noopener">voted to decriminalize the possession of cannabis for personal use</a>, marking a significant shift in the nation's drug policy. This decision, <a href="https://www.benzinga.com/markets/cannabis/24/06/39435078/brazil-on-the-brink-of-marijuana-decriminalization-supreme-court-to-decide-next-week" target="_blank" rel="noreferrer noopener">which addresses the application of Article 28 of the Drug Law from 2006</a>, aims to differentiate personal use from trafficking and could significantly reduce Brazil's prison overpopulation.
Under the current law in Brazil, the use of marijuana for scientific and medical use is legal, but cultivation is still illegal. This means that raw materials and oils must be imported and therefore are more expensive.
However, mothers of sick children in need of CBD-based medicine are continuing to lead the fight for reform that would allow easier and possibly free access to these life-saving plant-based medicines.
Continue reading Sá Pessoa&#8217;s story at the <a href="https://apnews.com/article/brazil-sao-paulo-medical-marijuana-epilepsy-d50fb583aa401bbed2af4aef5ec851b9" target="_blank" rel="noreferrer noopener">Associated Press</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/06/32693057/uk-moms-concern-as-no-doctor-will-prescribe-cannabis-for-her-daughters-300-daily-seizures" target="_blank" rel="noreferrer noopener">UK Mom&#8217;s Concern As No Doctor Will Prescribe Cannabis For Her Daughter&#8217;s 300 Daily Seizures</a></li>
</ul>
Photo: Courtesy of Africa Studio on Shutterstock

'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported results from a Phase 3 trial in Japan evaluating the safety and efficacy of cannabidiol oral solution, <a href="https://www.benzinga.com/topic/epidiolex" target="_blank" rel="noreferrer noopener">Epidiolex</a>, for treating seizures in children with rare forms of epilepsy, such as Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
While the trial did not achieve its primary goal of a significant reduction in seizure frequency, there were numeric improvements in other areas. Importantly, no new safety issues were found.
&#8220;We are confident in the overall clinical profile ofEpidiolex, which has been established in five Phase 3 clinical trials in more than 900 patients," stated Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "We believe the totality of the Epidiolexglobal data, including the findings from this trial, supports advancement of the program in Japan. We are continuing to collect data in Japanese patients and plan to engage with regulatory authorities in Japan regarding a potential new drug application (JNDA). We recognize the significant unmet need for patients in Japan living with rare epilepsies and thank the investigators, patients and caregivers who are involved in this trial.&#8221;
Read Also: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/03/37629667/time-is-still-the-enemy-says-mom-who-moved-mountains-for-her-epileptic-daughter-still-advocates-" rel="noreferrer noopener">Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter &amp; Still Advocates For Millions Of CBD Users</a>
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was<a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio" target="_blank" rel="noreferrer noopener"> acquired by</a> Jazz Pharmaceuticals in 2021. Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" target="_blank" rel="noreferrer noopener">for treating seizures related to tuberous sclerosis complex</a>.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
The trial is focused on measuring how much the seizure frequency changes over a treatment period of up to 16 weeks in 62 children aged 1 to 18 years old. The trial is still ongoing to gather more data on how well the treatment works and its safety for both children and adults in Japan.
<h2 class="wp-block-heading">Price Action</h2>
Jazz Pharmaceuticals' shares are trading down 4.36% on Friday morning, at $109.55 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/01/36870939/japanese-university-will-research-marijuanas-medical-uses-in-first-of-its-kind-collaboration-wit" target="_blank" rel="noreferrer noopener">Japanese University Will Research Marijuana&#8217;s Medical Uses In First-Of-Its-Kind Collaboration With Australian Company</a></li>
</ul>
Courtesy photo

The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex&#xAE;/Epidyolex&#xAE; globally) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC). The trial did not meet the primary efficacy endpoint of a pre-specified percentage change in indication-associated seizure frequency during the treatment period (up to 16 weeks) compared to baseline in Japanese pediatric patients; however, numeric improvements were observed in the primary and several secondary endpoints. No new safety signals were observed in the trial.

Global

Jazz Pharmaceuticals Provides Update On Cannabidiol Oral Solution Phase 3 Trial In Japan In Treatment-Resistant Epilepsies

Throughout the last three months, 12 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $166.92, a high estimate of $210.00, and a low estimate of $113.00. A 3.36% drop is evident in the current average compared to the previous average price target of $172.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1724076051_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Jazz Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Madhu Kumar</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$169.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Jazz Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>A Deep Dive into Jazz Pharmaceuticals's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.95% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.52%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.49%, the company showcases effective utilization of assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 1.54, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and raises the price target from $190 to $202.

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202

Axsome Therapeutics&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company&#39;s portfolio.
The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.
Axsome is also conducting several label expansion studies on Auvelity targeting other central nervous system&nbsp;disorders like Alzheimer&#39;s disease (AD) associated agitation and smoking cessation.
Currently, two separate phase III studies are evaluating Auvelity for treating agitation associated with AD. Top-line data from both studies are expected later in the second half of 2024.
AXSM is planning to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2024.
The successful development and subsequent commercialization of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year. Sunosi has become an important revenue driver for Axsome.
In February 2023, AXSM entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and certain Middle East/North African countries. Axsome receives royalties on Sunosi sales in out-licensed territories.
Axsome has an impressive portfolio of pipeline candidates, including AXS-07, AXS-12 and AXS-14. All of these are being developed for various CNS indications.
AXS-07 is being developed for the acute treatment of migraine. After several delays, the company resubmitted its NDA for AXS-07 to the FDA for the acute treatment of migraine in the second quarter of 2024. A decision from the regulatory body is expected within six months.
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large on the company in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acad#NASDAQ">ACAD</a>), which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications.
ACAD&#39;s Nuplazid is already approved for hallucinations and delusions associated with Parkinson&#39;s disease psychosis.
Acadia is also studying pimavanserin for the treatment of other CNS disorders.
<a href="https://www.zacks.com/stock/news/2322688/axsome-axsm-banks-on-auvelity-sunosi-to-fuel-growth?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2322688">To read this article on Zacks.com click here.</a>

ACAD

Axsome Banks on Auvelity & Sunosi to Fuel Growth

Throughout the last three months, 11 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $163.73, a high estimate of $210.00, and a low estimate of $113.00. A 4.25% drop is evident in the current average compared to the previous average price target of $171.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1722531820_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Jazz Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Madhu Kumar</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$169.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jazz Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Financial Insights: Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 1.03%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.39%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $188 to $166.Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $188 to $166.

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166

Russell companies with the lowest tax rates expected to generate $1B in 2025 – GS

50 stocks to invest during the bull steepening – Part 2

In a report released today, Ami Fadia from Needham maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price target of...

Needham Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Jefferies analyst Akash Tewari maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $154.00. Th...

Jefferies Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a pr...

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Stifel Nicolaus

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Stock moves reflect downgrade for US economic growth outlook - Goldman

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Jazz Pharmaceuticals (JAZZ – Research Report). The company's sh...

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Zymeworks Approaching A Moment Of Truth With Zanidatamab

ACGL

ALGN

ALLY

ALXO

AMAT

AMKR

APPF

ARES

AVGO

AZNCF

BEPC

BGNE

BILL

BRBR

CACI

CAVA

CELH

CRWD

CWST

DASH

DOCU

ELAN

EXLS

FRPT

FSLR

FTNT

GKOS

GMED

HSIC

INTC

IONS

IPGP

ITCI

KEYS

KLAC

LBRDK

LRCX

MASI

MCHP

MNST

MPWR

MRVL

ORCL

PCTY

PINS

PLTR

POST

QCOM

REGN

ROKU

SMCI

SNPS

SNYNF

SPOT

SPXU

SRPT

SWKS

TRGP

TRMB

UBER

UPRO

VLTO

XLRE

ZYME

Press Releases

MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy

Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Offerings

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

INCY

MIRA

SAVA

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Intérêt court

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL